Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | PABPC1 | P11940 | 4/20 | 0.63 |
| ▸ | EIF4H | Q15056 | 4/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645379 | 1.00 | MEN1 (1.00) | MEN1KMT2ACLK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29728200 | 1.00 | MEN1 (1.00) | MEN1KMT2ACLK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13113090 | 0.88 | MEN1 (0.79) | MEN1KMT2ACLK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL27599336 | 0.86 | MEN1 (0.76) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL8620986 | 0.85 | MEN1 (0.73) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL13609774 | 0.84 | MEN1 (0.73) | MEN1KMT2ACLK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL27599072 | 0.83 | MEN1 (0.71) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL27489211 | 0.83 | MEN1 (0.71) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL8110781 | 0.83 | MEN1 (0.70) | MEN1KMT2ACLK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8402846 | 0.83 | ALDH1A1 (0.74) | MEN1KMT2ACLK1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1330657-C | Piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | CN | claimed |
| CN-1434827-A | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | claimed |
| EP-2874987-B1 | alpha-AND gamma-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20190201365-A1 | ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2019-07-04 | — | — | US | disclosed |
| US-20170216241-A1 | ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-08-03 | — | — | US | disclosed |
| US-9604904-B2 | Alpha- and gamma-truxillic acid derivatives and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-03-28 | — | — | US | disclosed |
| WO-2014015276-A1 | α-AND γ-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2014-01-23 | — | — | WO | disclosed |
| US-8530646-B2 | Oxazolidinone derivative having 7-membered hetero ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-09-10 | — | — | US | disclosed |
| WO-2010139483-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | disclosed |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. | 2010-10-07 | — | — | US | disclosed |
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-6825351-B2 | SELECTIVE HYDROGENATION OF AMINO-SUBSTITUTED FUSED BICYCLIC AROMATIC RING SYSTEM, PREPARATION OF RACEMIC AMINO SUBSTITUTED FUSED BICYCLIC RING SYSTEM VIA NITROSATION, ENZYMATIC RESOLUTION OF RACEMIC MIXTURE TO PRODUCE (R)- AND (S)-FORMS | ANORMED, INC. (CA) | 2004-11-30 | — | — | US | disclosed |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-6750348-B1 | PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE | ANORMED, INC. (CA) | 2004-06-15 | — | — | US | disclosed |
| CN-1436232-A | Variants with altered properties | NOVOZYMES AS (DK) | 2003-08-13 | — | — | CN | disclosed |
| CN-1434827-A | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED CORPORATION (CA) | 2003-06-19 | — | — | US | disclosed |
| WO-2003022785-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2003-03-20 | — | — | WO | disclosed |
| EP-1163238-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056729-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201365-A1 | ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | FABP1, FABP2, FABP7 | MEN1 4872/4885KMT2A 4598/4885CLK1 4842/4885 |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | MEN1 4063/4885KMT2A 1706/4885CLK1 1177/4885 |
| US-20170216241-A1 | ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | FABP1, FABP2, FABP7 | MEN1 4872/4885KMT2A 4598/4885CLK1 4842/4885 |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | NR0B2, NR0B1, NR2C2 | MEN1 3897/4885KMT2A 3553/4885CLK1 1962/4885 |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | MEN1 4366/4885KMT2A 4002/4885CLK1 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.